Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of an anticoagulant and an antiplatelet refers to the concurrent use of two classes of blood-thinning medications, each with a distinct mechanism for reducing the risk of blood clots. Anticoagulants (such as warfarin, heparin, apixaban, rivaroxaban) inhibit specific proteins in the coagulation cascade to prevent clot formation. Antiplatelets (such as aspirin, clopidogrel, prasugrel, ticagrelor) prevent platelets from aggregating and forming clots. This combination is often used in patients at high risk for thrombotic events—such as those with atrial fibrillation who have undergone stenting or have acute coronary syndromes—to provide enhanced protection against heart attack and stroke. However, combining these agents increases bleeding risk and requires careful clinical monitoring[2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anticoagulant + antiplatelet.